You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 279 No. 7, February 18, 1998 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Health Agencies Update
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Anti-AIDS Gene Therapy

Joan Stephenson, PhD

JAMA. 1998;279:494.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A form of gene therapy tested in the best available animal model for human immunodeficiency virus (HIV) infection appears to reduce the pathogenicity of such viruses, report scientists at the National Institutes of Health, Bethesda, Md, and The Johns Hopkins University School of Medicine, Baltimore, Md (Nat Med. 1998;4:181-186).

The investigators tested the therapy in rhesus macaques, which develop an AIDS-like disease when infected with simian immunodeficiency virus (SIV). The experimental therapy targets retroviral RNA genes called tat and rev that code for 2 proteins needed for both HIV and SIV to reproduce in infected CD4 cells. The approach uses antisense RNA, a strand of nucleic acid that corresponds to and binds to genes—in this case, the tat and rev genes. The resulting double-stranded RNA molecule encourages the degradation of SIV RNA and interferes with the ability of the retroviral RNA to direct the production of . . . [Full Text of this Article]







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.